Abbott Laboratories

132.60
-4.76 (-3.47%)
At close: Mar 11, 2025, 3:59 PM
133.16
0.43%
After-hours: Mar 11, 2025, 08:00 PM EDT
-3.47%
Bid 132.08
Market Cap 229.97B
Revenue (ttm) 42.01B
Net Income (ttm) 13.42B
EPS (ttm) 7.64
PE Ratio (ttm) 17.36
Forward PE 22.46
Analyst Buy
Ask 134.25
Volume 6,615,370
Avg. Volume (20D) 6,348,634
Open 136.50
Previous Close 137.36
Day's Range 132.31 - 137.06
52-Week Range 99.71 - 141.23
Beta 0.69

About ABT

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepa...

Sector Healthcare
IPO Date Mar 17, 1980
Employees 114,000
Stock Exchange NYSE
Ticker Symbol ABT
Full Company Profile

Analyst Forecast

According to 16 analyst ratings, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $135, which is an increase of 1.81% from the latest price.

Stock Forecasts

Next Earnings Release

Abbott Laboratories is scheduled to release its earnings on Apr 16, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+4.62%
Abbott shares are trading higher after multiple an... Unlock content with Pro Subscription
4 months ago
+4.61%
Abbott Laboratories shares are trading higher after the company announced it along with Reckitt Benckiser won its first trial in premature-infant formula litigation and is cleared of allegations of hiding bowel disease risks.